藥學雜誌電子報137期 | 合法藥品大搜索

2018年12月31日—...及ponatinib，可用於治療新診斷、對imatinib有抗藥性或無法耐受之CML。不同的酪胺酸激酶抑制劑的突變作用點及副作用皆不同，可依病人 ...

You-An Shih, Wen-Hsun Lee, Hui-Chuan Hsiao, Hsiu-Mei Chang, Wei-Hsuan Huang Department of Pharmacy, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University Hospital, Kaohsiung Medical University

Chronic myeloid leukemia (CML) is a hematopoietic stem cell disease. Tyrosine kinase inhibitors (TKIs) are the initial targeted therapies for CML. Imatinib is the first generation of TKI which has been proven to be effective in BCR-ABL tyrosine kinase. As a result of mutations in the kinase domain of BCR-ABL, the second and the third generation of TKIs have been developed, such as nilotinib, dasatinib, bosutinib, ponatinib. They are approved for the treatment of newly diagnosed or imatinib-resistant or -intolerant CML. There are different selectivities for BCR-ABL, and different side effects for TKIs’. Appropriate medications could be chosen based on the need of patients’ spec...